As of 2025-09-18, the EV/EBITDA ratio of Acceleron Pharma Inc (XLRN) is -41.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acceleron's latest enterprise value is 10,456.47 mil USD. Acceleron's TTM EBITDA according to its financial statements is -253.46 mil USD. Dividing these 2 quantities gives us the above Acceleron EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.5x - 14.5x | 13.0x |
| Forward P/E multiples | 11.3x - 16.7x | 13.6x |
| Fair Price | (42.53) - (55.38) | (50.26) |
| Upside | -123.8% - -131.0% | -128.1% |
| Date | EV/EBITDA |